iSAM Funds UK Ltd Invests $4.88 Million in Merck & Co., Inc. $MRK

iSAM Funds UK Ltd bought a new stake in Merck & Co., Inc. (NYSE:MRK) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 58,095 shares of the company’s stock, valued at approximately $4,876,000. Merck & Co., Inc. comprises approximately 1.0% of iSAM Funds UK Ltd’s portfolio, making the stock its largest holding.

Other institutional investors and hedge funds have also modified their holdings of the company. Chemung Canal Trust Co. grew its stake in shares of Merck & Co., Inc. by 21.1% during the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock valued at $6,407,000 after purchasing an additional 13,285 shares during the last quarter. First Pacific Financial raised its position in Merck & Co., Inc. by 14.7% in the 3rd quarter. First Pacific Financial now owns 47,555 shares of the company’s stock worth $3,991,000 after purchasing an additional 6,082 shares during the last quarter. Diversified Trust Co raised its position in Merck & Co., Inc. by 9.6% in the 3rd quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock worth $17,444,000 after purchasing an additional 18,187 shares during the last quarter. Caxton Associates LLP lifted its holdings in Merck & Co., Inc. by 23.3% during the 2nd quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock worth $3,121,000 after buying an additional 7,458 shares in the last quarter. Finally, NEOS Investment Management LLC boosted its position in Merck & Co., Inc. by 39.9% in the 3rd quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock valued at $29,181,000 after buying an additional 99,074 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Richard R. Deluca sold 37,685 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the sale, the executive vice president directly owned 160,174 shares of the company’s stock, valued at $19,368,240.08. This represents a 19.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the sale, the executive vice president directly owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Price Performance

MRK opened at $115.61 on Friday. The company has a fifty day moving average price of $115.26 and a two-hundred day moving average price of $99.58. The firm has a market capitalization of $285.84 billion, a PE ratio of 15.88, a P/E/G ratio of 2.24 and a beta of 0.27. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the prior year, the business posted $1.72 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Analyst Ratings Changes

Several research firms have recently commented on MRK. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price for the company in a research note on Thursday, January 8th. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their price target for the company from $82.00 to $130.00 in a research note on Thursday, December 18th. Cantor Fitzgerald raised their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Citigroup lifted their price objective on Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Finally, Royal Bank Of Canada began coverage on Merck & Co., Inc. in a report on Wednesday, February 25th. They set an “outperform” rating and a $142.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $126.81.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.